

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 March 2003 (27.03.2003)

PCT

(10) International Publication Number
WO 03/024926 A2

(51) International Patent Classification⁷: **C07D**

(21) International Application Number: PCT/US02/30177

(22) International Filing Date:
23 September 2002 (23.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/324,147 21 September 2001 (21.09.2001) US

(71) Applicant (for all designated States except US): **REDDY US THERAPEUTICS, INC.** [US/US]; 3065 Northwoods Circle, Norcross, GA 30071-1542 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TIMMER, Richard, T.** [US/US]; 1729 Coventry Road, Decatur, GA 30030 (US). **ALEXANDER, Christopher, W.** [US/US];

211 Wynfield Trace, Norcross, GA 30092 (US). **PIL-LARISSETTI, Sivaram** [IN/US]; 4762 Grand Heron Court, Norcross, GA 30092 (US). **SAXENA, Uday** [IN/US]; 2900 Galahad Drive, Atlanta, GA 30345 (US). **CAMPBELL, Karen, A.** [CA/US]; 5925 Rustic Wood Lane, Durham, NC 27713 (US).


(74) Agents: **MERCHANT, Mary, Anthony** et al.; Kilpatrick Stockton LLP, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS



(57) Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.



WO 03/024926 A2



ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *without international search report and to be republished upon receipt of that report*